Enliven Therapeutics, Inc.
ELVN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,059,143 | $491,957 | $102,234 | $70,326 |
| - Cash | $124,117 | $100,141 | $75,536 | $110,024 |
| + Debt | $0 | $335 | $323 | $159 |
| Enterprise Value | $935,026 | $392,151 | $27,021 | -$39,539 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$104,237 | -$83,232 | -$38,576 | -$24,647 |
| % Margin | – | – | – | – |
| Net Income | -$89,024 | -$71,584 | -$37,662 | -$24,740 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.89 | -2.01 | -6.03 | -3.17 |
| % Growth | 6% | 66.7% | -90.2% | – |
| Operating Cash Flow | -$73,192 | -$61,269 | -$32,077 | -$19,134 |
| Capital Expenditures | -$44 | -$149 | -$612 | -$191 |
| Free Cash Flow | -$73,236 | -$61,418 | -$32,689 | -$19,325 |